FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Biogen Defends Anti-Tau Alzheimer's Data After Investor Selloff

[ Price : $8.95]

Biogen executives attempt to reassure investors Tuesday that its experimental anti-tau Alzheimer's disease therapy remains a promi...

Keep Safety and Dosing Info in Valtoco Label: Petition

[ Price : $8.95]

Neurelis petitions FDA to ensure that any generic version of diazepam nasal spray is no less safe and effective than its Valtoco f...

Pallone Asks GAO to Analyze RIF Impact on User Fees

[ Price : $8.95]

House Energy and Commerce Committee ranking member Frank Pallone asks the Government Accountability Office to analyze how FDA paid...

Yale, Harvard Experts Call for Greater FDA Transparency To Rebuild Public Trust

[ Price : $8.95]

A group of academic and public health experts urges FDA to embrace greater transparency, scientific independence and regulatory co...

Full Approval Given to Lilly's Retevmo

[ Price : $8.95]

FDA converts the accelerated approval of Eli Lilly's Retevmo (selpercatinib) into a traditional approval for treating adult and pe...

FDA Updates Bioequivalence Guidance for Generic Topical Corticosteroids

[ Price : $8.95]

FDA finalizes updated guidance for industry outlining current recommendations for demonstrating bioequivalence of generic topical ...

Hearing to Examine FDA's Role in Strengthening U.S. Drug Development

[ Price : $8.95]

The House Energy and Commerce Subcommittee on Health plans a hearing 7/15 to examine how FDA can help strengthen U.S. leadership i...

DTC Advertising Industry Braces for Potential End of Adequate Provision

[ Price : $8.95]

DTC Perspectives CEO Bob Ehrlich warns that an upcoming FDA proposal to eliminate the adequate provision standard could amount to ...

Ascelia Clarifies CRL on MRI Agent After Public Release

[ Price : $8.95]

Ascelia Pharma pushes back against FDA's recent public release of a Complete Response Letter for its MRI contrast agent Orviglance...

GSKs Jemperli Trial Meets Endpoint in Rectal Cancer

[ Price : $8.95]

GSK says its PD-1 inhibitor Jemperli (dostarlimab) achieved the primary endpoint in a registrational Phase 2 trial in patients wit...